Singapore markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
692.18+0.36 (+0.05%)
As of 03:33PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 75.41B
Enterprise value 70.55B
Trailing P/E 13.84
Forward P/E 14.27
PEG Ratio (5 yr expected) 4.64
Price/sales (ttm)5.53
Price/book (mrq)3.65
Enterprise value/revenue 4.96
Enterprise value/EBITDA 10.54

Trading information

Stock price history

Beta (5Y monthly) 0.28
52-week change 321.20%
S&P500 52-week change 3-16.45%
52-week high 3754.67
52-week low 3538.01
50-day moving average 3635.32
200-day moving average 3636.72

Share statistics

Avg vol (3-month) 3678.36k
Avg vol (10-day) 3790.3k
Shares outstanding 5107.19M
Implied shares outstanding 6N/A
Float 8102.28M
% held by insiders 12.59%
% held by institutions 189.79%
Shares short (30 Aug 2022) 42.91M
Short ratio (30 Aug 2022) 45.37
Short % of float (30 Aug 2022) 42.83%
Short % of shares outstanding (30 Aug 2022) 42.67%
Shares short (prior month 28 Jul 2022) 43.07M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin 39.97%
Operating margin (ttm)49.77%

Management effectiveness

Return on assets (ttm)18.18%
Return on equity (ttm)31.76%

Income statement

Revenue (ttm)14.23B
Revenue per share (ttm)133.27
Quarterly revenue growth (yoy)-44.40%
Gross profit (ttm)10.73B
EBITDA 7.38B
Net income avi to common (ttm)5.69B
Diluted EPS (ttm)50.63
Quarterly earnings growth (yoy)-72.50%

Balance sheet

Total cash (mrq)7.57B
Total cash per share (mrq)70.78
Total debt (mrq)2.7B
Total debt/equity (mrq)13.06
Current ratio (mrq)5.12
Book value per share (mrq)192.62

Cash flow statement

Operating cash flow (ttm)8.45B
Levered free cash flow (ttm)6.24B